| | | |

CRISPR Gene Editing Technique and the Future of Mesothelioma Treatment

ByAlex Strauss
CRISPR gene editing technique

The powerful CRISPR gene editing technique might have a role to play in the future of mesothelioma treatment.

CRISPR is a method for altering certain genes to help fight disease. This week, scientists at the University of Pennsylvania released data from the first study of CRISPR in US cancer patients. 

It was only a safety study, but the results are promising. They could have wide-ranging implications for patients fighting aggressive cancers like malignant mesothelioma. 

Modifying Genes To Help Fight Cancer

The CRISPR gene editing technique is a simplified version of the method bacteria cells use to defend themselves against viruses. This antiviral defense system is called CRISPR-Cas9.

The new Penn Medicine study involved just three cancer patients. Two of the patients had multiple myeloma and one had sarcoma. 

Doctors removed some immune system cells from the patients. They modified the cells in a lab using the CRISPR gene editing technique. The cells were “reprogrammed” to be more aggressive against cancer cells. Then the cells were returned to the patients via infusion.

The technique combines genetic modification with immunotherapy. Immunotherapy harnesses the power of the immune system to fight disease. Immunotherapy is one of the most talked-about new approaches to mesothelioma treatment.

Mesothelioma is rare but still affects about 2,500 US patients each year. These patients have very few treatment options. Many die within a year of diagnosis. 

CRISPR Gene Editing Could be Safe for Mesothelioma Patients

The cancer patients whose cells were modified with CRISPR did not have any significant side effects. The treatment appears to do what doctors hoped it would do. The next step is to study the CRISPR gene editing technique in a bigger group of cancer patients.

The Penn Medicine researchers will present their findings at the American Society of Hematology meeting in Florida next month. It could open the door for testing CRISPR in patients with mesothelioma and other types of cancer. 

In related news, Swiss scientists used a CRISPR-Cas9-based screening tool to identify genes that help mesothelioma cells survive. One of those was an enzyme called WEE1.

It turns out that blocking WEE1 makes mesothelioma cells more sensitive to chemotherapy. “Our results suggest a new therapeutic combination for malignant pleural mesothelioma,” writes lead author Duo Xu.

Dr. Xu says the study supports using CRISPR-Cas9-based genomics to improve existing cancer treatments. 

The CRISPR gene editing technique is still highly experimental. It is not yet available for routine use in the treatment of mesothelioma patients. 

Sources:

Xu, D, et al, “CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma”, November 6, 2019, Molecular Cancer Therapeutics, Epub ahead of print, https://mct.aacrjournals.org/content/early/2019/11/06/1535-7163.MCT-19-0724

Stein, Rob, “CRISPR Approach To Fighting Cancer Called ‘Promising’ In 1st Safety Test”, November 6, 2019, National Public Radio (NPR), November 6, 2019, https://www.npr.org/sections/health-shots/2019/11/06/776169331/crispr-approach-to-fighting-cancer-called-promising-in-1st-safety-test

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…